ExpressPoints: Immunotherapy in SCLC: Challenges and Opportunities of Rapidly Evolving Treatments

Download this short summary slideset of key takeaways from a live CCO Webinar focused on key data informing the optimal use of immune checkpoint inhibition for the treatment of advanced SCLC.
Anna F. Farago, MD, PhD
Taofeek K. Owonikoko, MD, PhD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.18 MB
Released: July 15, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.

Related Content

In this slideset from Clinical Care Options (CCO), Edward S. Kim, MD, FACP offers insight on using biomarkers for optimal therapy selection in NSCLC

Edward S. Kim, MD, FACP Released: October 15, 2020

In this slideset from Clinical Care Options (CCO), Sandip P. Patel, MD offers insight on therapeutic agents directed to emerging biomarkers in NSCLC

Sandip P. Patel, MD Released: October 15, 2020

Downloadable slideset on best practices for biomarker testing in the treatment of patients with advanced NSCLC, from Clinical Care Options (CCO)

Lauren L. Ritterhouse, MD Released: October 13, 2020

Downloadable slideset on established and emerging biomarkers critical to optimal use of targeted therapy and immunotherapy in NSCLC, from Clinical Care Options (CCO)

Joel W. Neal, MD, PhD Released: October 13, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue